Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;22(4):1149-1156.
doi: 10.31557/APJCP.2021.22.4.1149.

Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy

Chaichana Chantharakhit  1 , Nantapa Sujaritvanichpong  1
Affiliations

Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy

Chaichana Chantharakhit et al. Asian Pac J Cancer Prev. .

Abstract

Background: The advanced lung cancer inflammation index (ALI) has been reported to predict the overall survival in patients with advanced non-small cell lung cancer (NSCLC). However, no previous studies have examined the prognostic significance of ALI in metastatic NSCLC treated with first line chemotherapy. The objective of this study was to explore the relationship between ALI and the prognosis of metastatic NSCLC treated with first line chemotherapy.

Materials and methods: Data of 109 metastatic NSCLC patients who had completed first line treatment with chemotherapy was collected. A multivariate flexible parametric proportional-hazards model with restricted cubic splines (RCS) was used to explore and identify the independent prognostic factors, including clinical potential factors and ALI for the overall survival. Multivariate regression analysis was used to evaluate the potential prognostic factors associated with short survival less than 6 months. The analysis of the restricted mean survival time (RMST) method was used to estimate the event-free time from zero to 18 months.

Results: The median OS was 10.9 months (95%CI 9.57-13.18) and median PFS was 7.5 months (95%CI 6.85-8.00).The multivariate survival analyses revealed two prognostic factors for worse survival: Poor ECOG PS (HR46.90; 95%CI 2.90-758.73; p=0.007) and progressive disease after completing the first line chemotherapy treatment (HR 2.85; 95%CI1.18-6.88; p=0.02),whereas a low ALI.

Keywords: Lung cancer; Prognostic factors; Survival Analysis; advanced lung cancer inflammation index (ALI).

PubMed Disclaimer

Conflict of interest statement

The authors confirm that there are no relevant financial or non-financial competing interests to report and no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier Curve of the PFS and OS (mPFS 7.5 months, mOS 10.9 months)
Figure 2
Figure 2
The Area under the Receiver Operating Characteristic Curve (ROC curve) of ALI when using the Cut-off Point <11 to Predict the Probability of Death, AUC 0.52 (95% CI 0.45-0.60).
Figure 3
Figure 3
Kaplan-Meier Estimates of Overall Survival, According to Significant Prognostic Factors by Univariate Analysis
See this image and copyright information in PMC

References

    1. Akinci Ozyurek B, Sahin Ozdemirel T, Buyukyaylaci Ozden S, et al. Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases. Asian Pac J Cancer Prev. 2017;18:1417–21. - PMC - PubMed
    1. Arenberg DA, Kunkel SL, Polverini PJ, et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996;97:2792–802. - PMC - PubMed
    1. Bacha S, Sghaier A, Habibech S, et al. Advanced Lung Cancer Inflammation index: a prognostic score in patients with metastatic non-small cell lung cancer. Tunis Med. 2017;95:976–81. - PubMed
    1. Berardi R, Santoni M, Rinaldi S, et al. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Ann Transl Med. 2019;7:572. - PMC - PubMed
    1. Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015;33:1008–14. - PMC - PubMed